Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19
The main basis for hydroxychloroquine (HCQ) treatment in COVID-19 is the compound’s ability to inhibit viral replication in vitro. HCQ also suppresses immunity, mainly by interference in TLR signalling, but reliable clinical data on the extent and nature of HCQ-induced immunosuppression are lacking....
Saved in:
Main Authors: | Aliede E. in ‘t Veld, Manon A. A. Jansen, Luuk C. A. Ciere, Matthijs Moerland |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2021/6659410 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of hydroxychloroquine prescriptions for COVID‐19 in Japan
by: Takashi Watari, et al.
Published: (2023-05-01) -
Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19
by: George G. Zhanel, et al.
Published: (2021-01-01) -
COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia
by: Awan K. Rahman, et al.
Published: (2020-01-01) -
Knowledge on hydroxychloroquine prescription and attitude toward its use in COVID-19 – A survey-based study among doctors
by: T P Afra, et al.
Published: (2021-01-01) -
Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients
by: Seyed Parsa Eftekhar, et al.
Published: (2021-01-01)